BenchSci
Agent55Agent Readiness: 55/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust86Data Trust: 86/100. Top 25%. Measured by StartupHub.ai. Median 61.AI-powered platform for understanding disease biology and accelerating drug discovery.
About
BenchSci is building the world's first neuro-symbolic AI platform, ASCEND, to help scientists understand disease biology and accelerate drug discovery. ASCEND leverages a Biological Evidence Knowledge Graph (BEKG) and advanced AI to provide insights from diverse scientific data, including publications, multi-omics, and clinical trials. This platform aims to transform the drug discovery process by enabling R&D teams to go from hypothesis to successful experiment faster.
Listed competitors
Uses AI and automation to industrialize drug discovery and development for rare diseases and cancers.
Biotechnology company specializing in antibody discovery and development with integrated 'Idea to IND' solutions.
AI platform for discovering new medicines and transforming the drug development process.
Also in this space
Mapping and reprogramming the immune system with single-cell biology and AI for therapeutic discovery.
Shares Life Sciences, Biotech
AI-powered insights platform for life sciences and biotech workflows.
Shares Life Sciences, Biotech
AI-powered drug discovery platform for GPCR targets, accelerating development and reducing risk.
Shares Biotech, Drug Discovery
AI-guided drug discovery platform for tissue-targeted medicines.
Shares Biotech, Drug Discovery
Synthace provides a no-code cloud platform for life sciences R&D, enabling scientists to automate experimentation and insight sharing.
Shares Biotech, Drug Discovery
AI-powered platform for real-time organ physiology to accelerate human-relevant drug discovery.
Shares Biotech, Drug Discovery
Key facts
- Website
- benchsci.com
- Headquarters
- Toronto, Canada
- Founded
- 2015
- Employees
- 274
- Total funding
- $197M (Series D)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 25 May 2023 | Series D | $70M | Generation Investment Management |
| 1 Mar 2022 | Bridge | $28M | |
| 24 Jan 2022 | Series C | $50M | Inovia Capital, TCV |
| 1 Feb 2020 | Series B | $22M | |
| 1 Feb 2020 | Funding Round | $8M | |
| 1 Jun 2019 | Series A | $7M | |
| 1 May 2018 | Series A | $10M | Gradient Ventures |
| 1 Mar 2017 | Seed | $3M | |
| 1 Oct 2016 | Pre-Seed | $254K |
Tech stack
Detected on benchsci.com, last scanned 31 Oct 2026. Run your own scan
- Frontend
- Next.js, Tailwind CSS
- Auth
- Auth0
- Analytics
- Google Analytics 4
- Support
- HubSpot
- CMS / Builders
- Salesforce
- CDN
- Vercel
- Email provider
- Google Workspace
- Cookie consent
- OneTrust
BenchSci scores 60. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is BenchSci trustworthy and reputable?
StartupHub's Data Trust & Reputation score for BenchSci is 86 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has BenchSci raised?
BenchSci has raised a total of $197M in funding. The most recent round on record is Series D.
How many employees does BenchSci have?
BenchSci has approximately 274 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for BenchSci
